Pharmaceutical Technology

JULY 15, 2022

Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin. In-house manufacturing the norm.

Insulin 328

Insulin Manufacturing Contract Manufacturing Production 328

XTalks

FEBRUARY 8, 2024

Understanding the market dynamics of diabetes treatments becomes crucial for professionals across these industries. The top 15 diabetes drugs in 2023, according to 2022 sales data, reflect the current state of diabetes management and hint at the evolving needs and trends within this critical area of healthcare. billion in Q4 2022.

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

NOVEMBER 17, 2021

Following a soft launch in select markets, the beverage buffs behind Oatly and Fiji Water have teamed up to develop Good Idea , a functional beverage that will soon debut in the US. The drinks are available for sale on Good Idea’s website for a suggested retail price of $2.49, with retail locations to be announced.

Production 98

Production Marketing Insulin Packaging 98

pharmaphorum

AUGUST 11, 2020

Though Novo Nordisk is perhaps not as much of a household name as other pharma companies in the UK, it has a huge presence in diabetes, with a bigger market cap than the likes of GSK and AstraZeneca – and UK GM Pinder Sahota is keen to shout about the organisation that he describes as a “sleeping giant”. Collaborating to prevent diabetes.

Pharma Companies 111

Pharma Companies Insulin Packaging Packaging 111

Delveinsight

DECEMBER 29, 2020

Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. . billion – a deal that is split into upfront payments, and sales and regulatory milestone payments.

Trials 52

Trials Drugs Hormones Radiology 52

Pharma in Brief

AUGUST 9, 2021

The proposed amendments are intended to modernize the Canadian therapeutic product regulatory system at every stage of products’ lifecycles from authorization to post-market. Individual standards for certain biologic drugs ( e.g. , insulin) would be repealed in favor of relying on the standards set out in Schedule B to the Food and Drugs Act.

Regulation 98

Regulation Drugs Manufacturing Production 98

The Pharma Data

AUGUST 3, 2021

. – Second-quarter 2021 operating expenses increased 18 percent, driven primarily by higher research and development investments for late-stage assets, as well as higher relative marketing and selling expenses due to pandemic-related spending reductions in 2020. million of revenue from sales of COVID-19 antibodies.

Antibody 52

Antibody Sales Production Development 52